After a long wait, the result was still a ‘no go.’ A solution does exist, but hesitation seems to be holding them back.

The insurance reimbursement expansion for the 3rd-generation ALK anticancer drug Lorviqua to first-line therapy has become unclear again.

Negotiations between Pfizer Korea and the National Health Insurance Service on the drug price of the ALK-positive NSCLC treatment Lorviqua (lorlatinib), which passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review in January and began in March, recently broke down. This is the first time negotiations have broken down for a drug seeking reimbursement expansion risk-sharing agreemen